Junyelt

Copper gluconate, manganese gluconate, potassium iodide, sodium selenite, zinc gluconate, the active ingredients in Junyelt, are mineral supplements presented as an injectable solution for intravenous use. They provide essential trace minerals required for enzymatic activity and metabolic processes, helping to correct trace element deficiencies and support postoperative recovery in patients needing nutritional supplementation.

GNH USA supplies Junyelt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Junyelt is a mineral supplement administered intravenously to address conditions linked to trace element deficiency and postoperative metabolic stress. - Trace element deficiency: restores copper, manganese, iodine, selenium and zinc levels essential for enzyme function. - Nutritional support: supplies key minerals that aid overall metabolic health during periods of increased demand. - Postoperative recovery: assists in wound healing and immune function by providing cofactors for antioxidant and thyroid‑related enzymes.

Adverse reactions may occur with any intravenous mineral preparation. Monitoring and prompt reporting are advised.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the infusion site. - Transient fever: low‑grade temperature rise within hours. - Nausea or vomiting: mild gastrointestinal upset. - Headache: occasional dull headache during or after infusion. - Metallic taste: brief sensation in the mouth. - Mild hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergy requiring immediate medical intervention. - Severe electrolyte imbalance: abnormal serum levels of copper, zinc or manganese. - Acute renal dysfunction: impaired kidney function following infusion. - Thrombophlebitis: inflammation of the vein used for administration. - Hemolysis: destruction of red blood cells in rare cases. - Severe hypersensitivity: rash, bronchospasm, or angioedema.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications. - Baseline mineral assessment: measure serum copper, zinc, manganese, iodine and selenium levels. - Renal function monitoring: check creatinine and eGFR regularly. - Hypersensitivity screening: avoid in patients with known allergy to any component. - Pregnancy and lactation: use only if the potential benefit outweighs unknown risks. - Concomitant chelators: avoid simultaneous use of strong metal‑binding agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Junyelt may interact with other agents that affect mineral balance or share metabolic pathways.

Major Interactions (Avoid): - High‑dose oral copper or zinc supplements: risk of toxic accumulation. - Strong chelating agents (e.g., EDTA, dimercaprol): may reduce efficacy by binding administered minerals. - Parenteral iron formulations: competitive absorption may alter copper and zinc status.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: excess iodine can affect hormone levels. - Anticoagulants (warfarin, heparin): zinc may influence platelet function. - Diuretics (loop or thiazide): may exacerbate electrolyte shifts. - Antimicrobial agents (fluoroquinolones, tetracyclines): potential reduced absorption if oral supplements are used concurrently.